Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Background: The 4 serotypes of dengue virus, DENV-1-4, are the leading cause of arboviral disease globally. The ideal dengue vaccine would provide protection against all serotypes after a single dose.Methods: Two randomized, placebo-controlled trials were performed with 168 flavivirus-naive adults to demonstrate the safety and immunogenicity of a live attenuated tetravalent dengue vaccine (TV003), compared with those of a second tetravalent vaccine with an enhanced DENV-2 component (TV005), and to evaluate the benefit of a booster dose at 6 months. Safety data, viremia, and neutralizing antibody titers were evaluated.Results: A single dose of TV005 elicited a tetravalent response in 90% of vaccinees by 3 months after vaccination and a trivalent response in 98%. Compared with TV003, the higher-dose DENV-2 component increased the observed frequency of immunogenicity to DENV-2 in the TV005 trial. Both the first and second doses were well tolerated. Neither vaccine viremia, rash, nor a significant antibody boost were observed following a second dose.Conclusions: A single subcutaneous dose of TV005 dengue vaccine is safe and induces a tetravalent antibody response at an unprecedented frequency among vaccinees. A second dose has limited benefit and appears to be unnecessary. Studies to confirm these findings and assess vaccine efficacy will now move to populations in regions where DENV transmission is endemic.Clinical Trials Registration: NCT01072786 and NCT01436422.
    • Journal Subset:
      Biomedical; Editorial Board Reviewed; Peer Reviewed; USA
    • ISSN:
      0022-1899
    • MEDLINE Info:
      PMID: NLM25801652 NLM UID: 0413675
    • Grant Information:
      HHSN272200900010C//PHS HHS/United States; HHSN272200900010C/AO/NIAID NIH HHS/United States
    • Publication Date:
      20150923
    • Publication Date:
      20200708
    • PubMed Central ID:
      PMC4612392
    • DOI:
      http://dx.doi.org/10.1093/infdis/jiv082
    • Accession Number:
      109612868
  • Citations
    • ABNT:
      KIRKPATRICK, B. D. et al. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Journal of Infectious Diseases, [s. l.], v. 212, n. 5, p. 702–710, 2015. DOI 10.1093/infdis/jiv082. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=109612868. Acesso em: 13 ago. 2020.
    • AMA:
      Kirkpatrick BD, Durbin AP, Pierce KK, et al. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Journal of Infectious Diseases. 2015;212(5):702-710. doi:10.1093/infdis/jiv082
    • APA:
      Kirkpatrick, B. D., Durbin, A. P., Pierce, K. K., Carmolli, M. P., Tibery, C. M., Grier, P. L., Hynes, N., Diehl, S. A., Elwood, D., Jarvis, A. P., Sabundayo, B. P., Lyon, C. E., Larsson, C. J., Jo, M., Lovchik, J. M., Luke, C. J., Walsh, M. C., Fraser, E. A., Subbarao, K., & Whitehead, S. S. (2015). Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Journal of Infectious Diseases, 212(5), 702–710. https://doi.org/10.1093/infdis/jiv082
    • Chicago/Turabian: Author-Date:
      Kirkpatrick, Beth D, Anna P Durbin, Kristen K Pierce, Marya P Carmolli, Cecilia M Tibery, Palmtama L Grier, Noreen Hynes, et al. 2015. “Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.” Journal of Infectious Diseases 212 (5): 702–10. doi:10.1093/infdis/jiv082.
    • Harvard:
      Kirkpatrick, B. D. et al. (2015) ‘Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults’, Journal of Infectious Diseases, 212(5), pp. 702–710. doi: 10.1093/infdis/jiv082.
    • Harvard: Australian:
      Kirkpatrick, BD, Durbin, AP, Pierce, KK, Carmolli, MP, Tibery, CM, Grier, PL, Hynes, N, Diehl, SA, Elwood, D, Jarvis, AP, Sabundayo, BP, Lyon, CE, Larsson, CJ, Jo, M, Lovchik, JM, Luke, CJ, Walsh, MC, Fraser, EA, Subbarao, K & Whitehead, SS 2015, ‘Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults’, Journal of Infectious Diseases, vol. 212, no. 5, pp. 702–710, viewed 13 August 2020, .
    • MLA:
      Kirkpatrick, Beth D., et al. “Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.” Journal of Infectious Diseases, vol. 212, no. 5, Sept. 2015, pp. 702–710. EBSCOhost, doi:10.1093/infdis/jiv082.
    • Chicago/Turabian: Humanities:
      Kirkpatrick, Beth D, Anna P Durbin, Kristen K Pierce, Marya P Carmolli, Cecilia M Tibery, Palmtama L Grier, Noreen Hynes, et al. “Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.” Journal of Infectious Diseases 212, no. 5 (September 2015): 702–10. doi:10.1093/infdis/jiv082.
    • Vancouver/ICMJE:
      Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, et al. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Journal of Infectious Diseases [Internet]. 2015 Sep [cited 2020 Aug 13];212(5):702–10. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=109612868